DBV Technologies (NASDAQ:DBVT) Reaches New 1-Year Low - Time to Sell?

Key Points

• DBV Technologies shares fell to a new 52-week low, trading as low as $10.71 and last changing hands near $10.96, below its $11.21 prior close.
• Despite the decline, analysts maintain a generally positive outlook: five rate the stock Buy and one rates it Sell, producing a consensus “Moderate Buy” rating and a $48.50 price target.
• Institutional investors and hedge funds own approximately 71.74% of the company, while DBV continues developing Viaskin Peanut, an investigational patch for peanut allergies.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s share price hit a new 52-week low on Friday. The stock traded as low as $10.71 and last traded at $10.9550, with a volume of 80804 shares. The stock had previously closed at $11.21.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of DBV Technologies in a research note on Thursday, September 10th. Weiss Ratings cut DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, July 17th. Citigroup reiterated a "market outperform" rating on shares of DBV Technologies in a research report on Wednesday. Citizens Jmp increased their target price on DBV Technologies from $47.00 to $55.00 and gave the stock a "market outperform" rating in a report on Tuesday, June 30th. Finally, HC Wainwright restated a "buy" rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $48.50.

DBV Technologies Price Performance

The firm has a 50 day moving average price of $13.31 and a 200-day moving average price of $16.57. The firm has a market cap of $679.48 million, a price-to-earnings ratio of -3.08 and a beta of -1.04.

Institutional Trading of DBV Technologies

Hedge funds have recently modified their holdings of the company. Vivo Capital LLC grew its holdings in DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock valued at $55,726,000 after purchasing an additional 205,943 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of DBV Technologies in the 1st quarter valued at $21,159,000. Perceptive Advisors LLC bought a new stake in shares of DBV Technologies in the 1st quarter valued at $20,146,000. Atika Capital Management LLC increased its position in shares of DBV Technologies by 31.1% in the 1st quarter. Atika Capital Management LLC now owns 271,300 shares of the company's stock valued at $5,667,000 after buying an additional 64,419 shares in the last quarter. Finally, Elmind Capital LP acquired a new stake in DBV Technologies during the 1st quarter worth $5,536,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies' primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.